RENAL AL AMYLOIDOSIS

Clinical trials for RENAL AL AMYLOIDOSIS explained in plain language.

Never miss a new study

Get alerted when new RENAL AL AMYLOIDOSIS trials appear

Sign up with your email to follow new studies for RENAL AL AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Diabetes drug could help rare kidney disease patients

Disease control Recruiting now

This phase 2 trial tests whether dapagliflozin, a diabetes drug, is safe and can lower high urine protein levels in people with renal AL amyloidosis—a rare condition where abnormal proteins damage the kidneys. About 20 participants will take the drug daily for 6 months and be mon…

Matched conditions: RENAL AL AMYLOIDOSIS

Phase: PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control

Last updated Jun 28, 2026 00:00 UTC

RENAL AL AMYLOIDOSIS

Get alerted when new RENAL AL AMYLOIDOSIS trials appear

Diabetes drug could help rare kidney disease patients